Galmed Pharmaceuticals (GLMD) Change in Receivables (2013 - 2025)
Galmed Pharmaceuticals (GLMD) recorded quarterly Change in Receivables of $225000.0 in Q1 2025, little changed quarter-over-quarter from $226000.0 in Q1 2024, and little changed on a YoY basis from $226000.0 in Q1 2024.
Galmed Pharmaceuticals (GLMD) Change in Receivables (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Change in Receivables history runs 13 years deep, the most recent figure standing at $225000.0 for Q1 2025.
- In Q1 2025, Change in Receivables changed 0.44% year-over-year to $225000.0; the TTM figure through Mar 2025 stood at $46000.0 (up 110.15% YoY), while the FY2025 annual figure was -$240000.0, down 225.0% from the prior year.
- Change in Receivables was $225000.0 for Q1 2025 at Galmed Pharmaceuticals, roughly flat from $226000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.2 million in Q4 2021 to a low of -$400000.0 in Q4 2023.
- Historically, Change in Receivables has averaged $134428.6 across 5 years, with a median of -$5000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables slumped 123.32% in 2022, then surged 4620.0% in 2024.
- A 5-year view of Change in Receivables shows it stood at $1.2 million in 2021, then sank by 123.32% to -$274000.0 in 2022, then tumbled by 45.99% to -$400000.0 in 2023, then jumped by 156.5% to $226000.0 in 2024, then decreased by 0.44% to $225000.0 in 2025.
- The last three Change in Receivables figures came in at $225000.0 (Q1 2025), $226000.0 (Q1 2024), and -$400000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 225,000.00 |
| Mar 31, 2025 | 225,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Dec 31, 2023 | -400,000.00 |
| Dec 31, 2023 | -400,000.00 |
| Mar 31, 2023 | -5,000.00 |
| Mar 31, 2023 | -5,000.00 |
| Dec 31, 2022 | -274,000.00 |
| Dec 31, 2022 | -274,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Dec 31, 2021 | 1.18 Mn |
| Dec 31, 2021 | 1.18 Mn |
| Dec 31, 2020 | -200,000.00 |
| Dec 31, 2020 | -200,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Jun 30, 2020 | 121,000.00 |
| Jun 30, 2020 | 121,000.00 |